Dalia Abou Zeki, MD
Neurology · Charlotte, NCNPI 1730542606
Payments from drug & device makers
Across 107 payments — averaging $556.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$42K
- Genentech USA, Inc.$9K
- EMD Serono, Inc.$3K
- Amgen$2K
- Roche Products Limited$2K
- ANI Pharmaceuticals, Inc.$313
- plus $2K from 20 others
What the payments were for
- Consulting fees$9,23059%
- Speaking & faculty fees$2,25014%
- Travel & lodging$7255%
- Food & beverage$3,25021%
- Education$1001%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 6 | $42,358 |
| Genentech USA, Inc. | 13 | $8,617 |
| EMD Serono, Inc. | 13 | $2,636 |
| Amgen(2 entities) | 6 | $2,358 |
| Roche Products Limited | 6 | $1,614 |
| ANI Pharmaceuticals, Inc. | 6 | $313 |
| Eisai Inc. | 7 | $234 |
| Mallinckrodt Hospital Products Inc. | 7 | $218 |
| UCB, Inc. | 3 | $136 |
| AstraZeneca(2 entities) | 7 | $135 |
| Sanofi | 3 | $132 |
| E.r. Squibb & Sons, L.L.C. | 1 | $122 |
| Merz Pharmaceuticals, LLC | 7 | $120 |
| Lundbeck LLC | 3 | $90 |
| AbbVie(2 entities) | 4 | $75 |
| Novartis | 2 | $69 |
| Axsome Therapeutics, Inc. | 3 | $63 |
| Pfizer | 2 | $35 |
| GE HealthCare | 1 | $31 |
| Microtransponder, Inc. | 1 | $28 |
| Argenx US, Inc. | 1 | $27 |
| Johnson & Johnson | 1 | $26 |
| Acadia Pharmaceuticals Inc | 1 | $22 |
| Grifols USA, LLC | 1 | $18 |
| Vanda Pharmaceuticals Inc. | 1 | $17 |
| Biogen | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OCREVUS$8,454
- UPLIZNA$2,250
- Mavenclad$2,000
- PURIFIED CORTROPHIN GEL$150
- ZEPOSIA$122
- Ocrevus Zunovo$120
How this compares
$59,509 in reported general payments places this provider in the 80th percentile of 566 neurology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Carbidopa-LevodopaCarbidopa/Levodopa | 72 | $940 |
| Levetiracetam | 12 | $612 |
| Oxcarbazepine | 30 | $602 |
| Clonazepam | 18 | $301 |
| Gabapentin | 31 | $299 |
| Phenobarbital | 15 | $277 |
| Pregabalin | 15 | $158 |
| Baclofen | 14 | $129 |
| Primidone | 12 | $116 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 13 | $85 |
Paid to pharmacies, not to this prescriber.
Other neurology in Charlotte
- Mohammad BolouriCharlotte$16.6M
- T RaoCharlotte$4M
- Donna GravesCharlotte$1.8M
- Jill ConwayCharlotte$1.6M
- Matthew CarraroCharlotte$1.5M
- Urvi DesaiCharlotte$937K
- Ardith CourtneyCharlotte$862K
- Sanjay IyerCharlotte$685K
- Megan DonnellyCharlotte$601K
- Kenneth AshkinCharlotte$525K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.